Experienced in Generalized Tonic-Clonic Seizure

Maciej Maciejowski

Katowice, SL, PL 
Experienced in Generalized Tonic-Clonic Seizure
Katowice, SL, PL 
OverviewLocationsClinical Research

Overview

Maciej Maciejowski practices in Katowice, Poland. Mr. Maciejowski is rated as an Experienced expert by MediFind in the treatment of Generalized Tonic-Clonic Seizure. His top areas of expertise are Multiple Sclerosis (MS), CACH Syndrome, Seizures, and Relapsing Multiple Sclerosis (RMS).

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Generalized Tonic-Clonic Seizure.

Gender
Male

Locations

Katowice, SL, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® (CLARIFY MS)
A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® (CLARIFY MS)
Enrollment Status: Completed
Publish Date: September 14, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Enrollment Status: Terminated
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

8 Total Publications

Long-term cenobamate retention, efficacy, and safety: outcomes from Expanded Access Programme.
Long-term cenobamate retention, efficacy, and safety: outcomes from Expanded Access Programme.
Journal: Neurologia i neurochirurgia polska
Published: August 26, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Maciejowski's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile